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Purpose/Objective: Existing preclinical and clinical data 
suggest that the presence of a systemic inflammatory 
response plays a critical role in the progression of several 
solid tumors. The derived neutrophil-to-lymphocyte ratio 
(dNLR) represents an easily determinable marker of systemic 
inflammation and has been proposed as a potential 
prognostic marker. The present study was performed to 
externally validate the prognostic relevance of an elevated 
pre-treatment dNLR in a large cohort of non-metastatic 
breast cancer patients. 
Materials and Methods: Data from 762 consecutive non-
metastatic female breast cancer patients treated from 1999 
to 2004 were evaluated. Disease-free survival (DFS), distant 
metastases-free survival (DMFS), and overall survival (OS) 
were assessed using the Kaplan-Meier method. To evaluate 
the prognostic relevance, univariate and multivariate Cox 
regression models were performed for each endpoint. 
Results: Applying receiver-operating characteristics (ROC) 
analysis, the optimal cut-off level for the dNLR was 3. In 
univariate analysis, a dNLR ≥3 was associated with poor DFS 
(HR 1.87, 95%CI 1.28-2.73, p=0.001), DMFS (HR 1.90, 95%CI 
1.27-2.85, p=0.002), and OS (HR 1.67, 95%CI 1.07-2.63, 
p=0.025). Multivariate analysis revealed a significant 
association between the elevated dNLR and poor DFS (hazard 
ratio (HR) 1.70, 95%CI 1.09-2.65, p=0.018) and DMFS (HR 
1.66, 95%CI 1.02-2.68, p=0.041) but did not show a significant 
association between the dNLR and OS (HR 1.54, 95%CI 0.91-
2.59, p=0.106).  
Conclusions: In the present study, we confirmed the 
elevated pre-treatment dNLR as an independent prognostic 
factor that could be useful for future individual risk 
assessment in breast cancer patients.  
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Purpose/Objective: Intraoperative radiotherapy (IORT) has 
been proposed as alternative to external beam in early breast 
cancer however previous studies suggest that patient 
selection must be improved in order to reduce the rate of 
ipsilateral breast tumour recurrence (IBTR). 'Papa Giovanni 
XXIII' Hospital in Bergamo Italy has been authorized by 
Lombard Aldermanship to carry out a non-randomised study. 
The study was also approved by the local ethics committee. 
Materials and Methods: 735 procedures has been performed 
between February 2006 and June 2014, on 722 patients 
(mean age 64 years; range 48-84 years), 13 of them had 
doubled IORT (synchronous or metachronous). 
Patients inclusion/exclusion criteria were: Age > 48 years old 
(if postmenopausal); clinical, mammography/ultrasound 
diagnostic of unifocal invasive carcinoma with an ultrasound 
major diameter < 2.5 cm. Informed consent was mandatory. 
There were 41 protocol violations due the age or the nodule 
size, enclosed in the analysis. 
IORT was done by means of a 9 MeV electron beam Novac 7 
linac. The prescribed dose was 21 Gy at 90 % isodose. The 
mean follow up is 1564 days and all patients with at least one 
follow up are enclosed in the analysis. The principal endpoint 
was the in-field and out-field (IBTR), Relapse Free Survival 
(RFS). The secondary endpoints were the Overall Survival 
(OS), Cancer Specific Survival (CSS), Metastases Free Survival 
(MFS), Disease Free Survival (DFS) and the acute and late 
toxicity rates. 
Survival dependence on different parameters such as nodule 
size, ER, PR, focality, grade, vascular invasion, Ki67>20, 
margins, cErbB2, has been assessed by log-rank test. 
Results: Observed local relapses are 52 (33 in field, 17 out-
field, 2 n.o.s.), corresponding to a crude rate of 7.1 % the 5 
years cumulative RFS, DFS, MFS were 92.1%, 89% and 94.7% 
respectively. The 5 years OS and CSS were 98.8% and 99.4% 
respectively. 
The univariate statistical analysis showed that IBRT 
dependence on the independent variables: nodule size, ER, 
PR, focality, grade, vascular invasion, Ki67>20, margins, 
cErbB2 was statistically significant. Dependence on the other 
variables such as DCIS component, histological type, pN, 
showed a trend but is not statistically significant. This last 
result may be due to the dimension of subgroups. Concerning 
nodule dimension, the most significant difference in IBTR 
occurs when a cut-off value of 15 mm is used. 
Grouping the patients according to ASTRO guidelines for 
accelerated partial breast irradiation, patients scored in the 
'suitable' group showed a much better RFS as compared to 
'cautionary' or 'unsuitable' group. 
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Conclusions: At the moment the Partial Breast Irradiation is 
a procedure still under investigation as it is encumbered by 
high risk of local relapse as compared with external beam (OS 
is similar), as confirmed also by our study. Nevertheless it 
gained a great appeal among women and the IORT can be 
offered to accurately selected pts.  
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Purpose/Objective: Axillary lymph node dissection (ALND) 
and adjuvant radiotherapy (RT) in breast cancer is associated 
with a risk of severe morbidity including lymphoedema, 
impaired function of the arm and chronic pain/sensory 
disability. The aim of this study was to evaluate the 
morbidity in two groups of heavily treated adjuvant breast 
cancer patients, differing only regarding inclusion or not of 
regional nodes in the RT volume.  
Materials and Methods: 347 patients consecutively operated 
from 2007-2012 with breast conservative surgery (BCS) and 
ALND (>= 3 micro- or macrometastases in sentinel node (SN) 
or SN not identified). All patients received adjuvant taxane 
based chemotherapy and if indicated, trastuzumab and 
endocrine treatment. The RT consisted of whole breast 
irradiation (WBI) to patients with pN0 and pN1mi disease and 
loco-regional RT in case of >= pN1 disease. The dose was in 
all patients 50 Gy in 25 fx. Only patients without recurrence 
were eligible for the study. They were invited to participate 
in a cross-sectional study regarding evaluation of objective 
physical impairments, and filling out a questionnaire 
regarding morbidity.  
Results: 277 patients participated. Of these, 185 patients 
(>=pN1), median 15 removed axillary nodes, received loco-
regional RT, median follow up 3.3 years, while 92 patients 
(pN0, pN1mi), median 16 removed axillary nodes, received 
WBI, median follow up 4.3 years. 
Circumferential ipsilateral arm difference of >= 2 cm of 
upper and/or lower arm was seen in 18% after loco-regional 
RT and in 16% after WBI (p=0.67). An increase of >= 10 % in 
ipsilateral upper and/or lower arm circumference was seen in 
8% (loco-regional RT) vs 3% (WBI) (p=0.12) and if this was 
combined with weekly use of an arm sleeve these numbers 
were 19% (loco-regional RT) versus 15% (WBI) (p=0.39). Self 
reported lymphoedema of ipsilateral upper/lower arm was 
found in 44%/33% (loco-regional RT) and in 40%/29% after WBI 
(p=NS).  
Severe impairments of shoulder function with abduction to 
120° or less was 3% after both loco-regional RT and WBI and 
severe impairments of shoulder flexion to 120° or less were 
1% and 2%, respectively. In the contralateral arm severe 
reduction of abduction/flexion was seen in 0.7%. No 
differences in self reported physical impairment, pain or 
sensory disturbances were seen between the two groups. 
Conclusions: Clinical lymphoedema is seen in about 15-20% 
of patients after ALND and is not dependent on the type of 
RT (WBI or loco-regional RT). Severe impairment of shoulder 
function is rare and not influenced by including regional 
nodes in the RT volume. Awareness of morbidity is important 
to improve future treatment strategies in heavily treated 
breast cancer patients.  
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Purpose/Objective: To investigate the impact in locoregional 
recurrence (LRR) of omission of axillary irradiation (axillary 
level I-II) in patients with ≥7 pathological positive axillary 
lymph nodes (>7pN+) and to identify prognosis factors 
associated in breast cancer patients. 
Materials and Methods: A retrospective database was used to 
identify patients undergoing BCT (breast conserving 
treatment), adjuvant CT (chemotherapy) and radiation 
therapy (RT) from 2000 to 2011. Patients treated with neo-
adjuvant chemotherapy (NCT) were excluded. This study 
analysed 100 patients (34 pN2 and 66 pN3). RT was delivered 
to the chest wall or wall breast and internal lymph nodes 
[internal mammary chain (IMC), supraclavicular, 
infraclavicular and axillary level III]. Disease free survival 
(DFS), metastasis free survival 5(MFS) and overall survival 
were analysed using the Kaplan-Meier method and compared 
using the log-rank test. Cox's proportional hazards regression 
models.  
Results: With a median follow-up time of 63.2 months, 3 
patients relapsed in not irradiated axillary region (1 isolated 
and 2 concomitant with distant metastasis). The median 
removed lymph nodes were 16 and the median lymph node 
ratio (LNR) was 0.8. The five years DFS, MFS and OS was 50%, 
58% and 69.9% respectively. Univariate and multivariate 
analysis showed that triple-negative histologic subtype was 
associated with DFS (HR 3.34 [1.59 ; 7.05] ;p=0.02), MFS (HR 
3.85 [1.59 ;9.29]; p=0.003) and OS (HR 5.77 [2.41 ;13.80]; 
p<0.001). 
Conclusions: The omission of axillary irradiation (level I-II) in 
patient underwent to BCT with an appropriate axillary lymph 
node dissection showed a low rate of regional relapse. Triple-
negative histological subtype in the most important prognosis 
factor in this population. Further prospective studies are 
necessary to assess the clinical impact of the omission of 
axillary irradiation.  
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